Patents by Inventor Jason Baum

Jason Baum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230348543
    Abstract: Disclosed herein are nucleotide sequences encoding an insecticidal protein exhibiting Lepidopteran inhibitory activity, as well as novel insecticidal proteins referred to herein as a BCW 001, BCW 002, BCW 003, and BCW toxic protein-containing chimeras and BCW toxin insecticide, transgenic plants expressing the chimeras or the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample.
    Type: Application
    Filed: May 17, 2023
    Publication date: November 2, 2023
    Inventors: James A. BAUM, David J. BOWEN, Catherine A. CHAY, David J. CHI, William P. CLINTON, Crystal L. DART, Leigh ENGLISH, Stanislaw FLASINSKI, Victor M. GUZOV, Kevin A. JARRELL, Uma R. KESANAPALLI, Thomas M. MALVAR, Robert M. MCCARROLL, Jason S. MILLIGAN, Jay P. MORGENSTERN, Deborah G. RUCKER, Sara A. SALVADOR, Temple F. SMITH, Carlos E. SOTO, Collin M. STULTZ, Brian M. TURCZYK, Ty T. VAUGHN, Moritz W.F. VON RECHENBERG
  • Patent number: 11702455
    Abstract: Disclosed herein are nucleotide sequences encoding an insecticidal protein exhibiting Lepidopteran inhibitory activity, as well as novel insecticidal proteins referred to herein as a BCW 001, BCW 002, BCW 003, and BCW toxic protein-containing chimeras and BCW toxin insecticide, transgenic plants expressing the chimeras or the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: July 18, 2023
    Assignee: Monsanto Technology LLC
    Inventors: James A. Baum, David J. Bowen, Catherine A. Chay, David J. Chi, William P. Clinton, Crystal L. Dart, Leigh English, Stanislaw Flasinski, Victor M. Guzov, Kevin A. Jarrell, Uma R. Kesanapalli, Thomas M. Malvar, Robert M. McCarroll, Jason S. Milligan, Jay P. Morgenstern, Deborah G. Rucker, Sara A. Salvador, Temple F. Smith, Carlos E. Soto, Collin M. Stultz, Brian M. Turczyk, Ty T. Vaughn, Moritz W. F. Von Rechenberg
  • Patent number: 9938346
    Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: April 10, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
  • Publication number: 20180036395
    Abstract: Provided are methods for the administration of therapeutic bispecific anti-IGF-1R and anti-ErbB3 antibodies, either alone or in combination with other anti-cancer therapeutics.
    Type: Application
    Filed: May 17, 2017
    Publication date: February 8, 2018
    Inventors: Alexey Alexandrovich LUGOVSKOY, Jason BAUM, Sharlene ADAMS, Bryan JOHNSON, Jian TANG
  • Publication number: 20170233491
    Abstract: Disclosed herein are methods of treating pancreatic cancer in a human patient by co-administering istiratumab in combination with gemcitabine and nab-paclitaxel, and dosage regimens for the same.
    Type: Application
    Filed: January 19, 2017
    Publication date: August 17, 2017
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Alexey Alexandrovich LUGOVSKOY, Jason BAUM, Chrystal U. LOUIS
  • Publication number: 20170096492
    Abstract: Provided herein are compositions comprising anti-IGF-1R, anti-ErbB3 bispecific antibodies alone or in combination with other anti-cancer agents. Also provided are methods of treating a subject having cancer and methods for determining whether a patient with cancer is likely to respond to the compositions described herein.
    Type: Application
    Filed: August 19, 2016
    Publication date: April 6, 2017
    Inventors: Sharlene ADAMS, Jason BAUM, Michael CURLEY, Alexey Alexandrovich LUGOVSKOY
  • Publication number: 20170051063
    Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Application
    Filed: August 26, 2016
    Publication date: February 23, 2017
    Inventors: Jason BAUM, Bryan JOHNSON, Alexey Alexandrovich LUGOVSKOY, Lihui XU, Neeraj KOHLI, Jonathan Basil FITZGERALD, Sharlene ADAMS
  • Patent number: 9556274
    Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: January 31, 2017
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
  • Patent number: 9527914
    Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: December 27, 2016
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
  • Publication number: 20160137738
    Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Application
    Filed: September 17, 2015
    Publication date: May 19, 2016
    Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
  • Publication number: 20160122438
    Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Application
    Filed: February 27, 2013
    Publication date: May 5, 2016
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Jason BAUM, Bryan JOHNSON, Alexey Alexandrovich LUGOVSKOY, Lihui XU, Neeraj KOHLI, Jonathan Basil FITZGERALD, Sharlene ADAMS
  • Publication number: 20150231219
    Abstract: Provided are methods for the administration of therapeutic bispecific anti-IGF-1R and anti-ErbB3 antibodies, either alone or in combination with other anti-cancer therapeutics.
    Type: Application
    Filed: April 2, 2013
    Publication date: August 20, 2015
    Inventors: Alexey Alexandrovich Lugovskoy, Jason Baum, Sharlene Adams, Bryan Johnson, Jian Tang
  • Publication number: 20130236459
    Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Application
    Filed: February 27, 2013
    Publication date: September 12, 2013
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Jason BAUM, Bryan JOHNSON, Alexey Alexandrovich LUGOVSKOY, Lihui XU, Neeraj KOHLI, Jonathan Basil FITZGERALD, Sharlene ADAMS
  • Patent number: 8476409
    Abstract: Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: July 2, 2013
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
  • Publication number: 20120269812
    Abstract: Provided herein are novel monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. Novel antiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Application
    Filed: April 19, 2012
    Publication date: October 25, 2012
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Jason BAUM, Bryan JOHNSON, Alexey Alexandrovich LUGOVSKOY, Lihui XU, Neeraj KOHLI, Jonathan Basil FITZGERALD, Sharlene ADAMS
  • Publication number: 20050240430
    Abstract: Emergency situations can be difficult to manage in any business enterprise. Embodiments of the invention are directed to systems and methods that allow a business enterprise, such as a petrochemical plant, hospital, or high rise building, to manage information regarding an emergency situation. This management system is preferably capable of providing customized evacuation reports to various individuals throughout the business enterprise. Such customized evacuation reports may be useful, for example, in a petrochemical plant when weather conditions change rapidly rendering previous evacuation plans hazardous. Further, these customized reports also may be useful in predicting the location of various individuals within the business enterprise, which may be a difficult task in an emergency situation.
    Type: Application
    Filed: April 26, 2005
    Publication date: October 27, 2005
    Inventor: Jason Baum